congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
Prevalence of HER2-low and IHC >0 to <1+ in breast cancer and its concordance between historical and rescored results: A multi-center, retrospective study in China
Oral
Dato-DXd
SABCS 2023 | December 5-9, 2023
Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
Real-world experience with trastuzumab deruxtecan in patients with breast cancer: 6 month-interim analysis of an all-patient postmarketing surveillance in Japan
Poster
Other/Multi
SABCS 2023 | December 5-9, 2023
Real-world features and outcomes of young advanced breast cancer (aBC) patients (pts) from RegistEM (GEICAM/2014-03) study
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
RELATE 2: A real-world observational study assessing the feasibility, acceptability and perceived impacts of treatment-specific versions of the OWise digital health tracking app in patients receiving olaparib in early breast cancer or trastuzumab deruxtecan in metastatic breast cancer
Mini-Oral
T-DXd
SABCS 2023 | December 5-9, 2023
Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: A phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08)
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: An updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM study)
Poster
Dato-DXd
SABCS 2023 | December 5-9, 2023
TROPION-Breast04: A phase 3 study of neoadjuvant datopotamab deruxtecan (Dato-DXd) + durvalumab followed by adjuvant durvalumab vs standard of care in treatment-naive early-stage triple negative and HR-low/HER2– breast cancer
Poster
Other/Multi
SABCS 2023 | December 5-9, 2023
Unmet clinical need in patients with pre-treated hormone receptor-positive/HER2-negative (HR+/HER2–) metastatic breast cancer in routine care: A targeted literature review
Páginas:
1 2